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Abstract. Anaemia is a feature almost invariably com-
plicating chronic renal failure. Its pathophysiology is
multifactorial but the most important cause is erythro-
poietin (Epo) deficiency. However, either no relation or
even a weakly positive relation generally exists between
serum immunoreactive (i) Epo and haematocrit values
in uraemic anaemia, whereas in anaemias of non-renal
origin the correlation is most often strongly negative.
Recent evidence indicates that growth hormone also
stimulates erythropoiesis. Moreover, late erythroid pro-
genitor cells (CFU-E) require insulin and/or insulin-like
growth factor I (IGF-I) for development in vitro. IGF-I
has been shown to have a synergistic action with Epo.
We have measured serum iEpo and IGF-I levels in 17
haemodialysis patients with severe hyperparathyroid-
ism (mean ± SEM serum iPTH, 988 ± 88 pg/ml). Mean
age and duration of dialysis treatment were 46.1 ± 3.4
and 8.8 ± 1.0 years respectively. Mean haematocrit and
haemoglobin values wer 28.1 ± 1.7% and 9.39 ± 0.54
g/dl respectively. Mean serum iEpo and IGF-I levels
were 20.3 ± 4.7 mU/ml and 320 ± 20 ng/ml respectively
(normal values for serum iEpo and IGF-I, 17.9 ± 6 mU/
ml and 91 ± 23 ng/ml respectively). We found that
serum IGF-I concentrations were well correlated with
haematocrit values (r = 0.68, n = 15, /)<0.004) whereas
serum iEpo values were not (r = 0.41, n = 12, P =
0.18). IGF-I could therefore be an important factor
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regulating erythropoiesis in uraemic patients, at least
when associated with severe hyperparathyroidism.
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Introduction
Anaemia of moderate to severe degree is a feature
which almost invariably complicates chronic renal
failure (CRF). Its pathophysiology is multifactorial.
Several possible mechanisms have been described and
include decreased erythropoietin (Epo) production,
shortened red blood cell survival, retained inhibitors or
toxic substances that interfere with erythroid marrow
function, iron and folate deficiency, and blood loss.
However, the most important cause of end-stage renal
disease anaemia clearly appears to be relative Epo
deficiency [1].
Secondary hyperparathyroidism in haemodialysis
patients has also been considered as a likely factor
predisposing to anaemia [2,3]. However, no correlation
has been found between serum intact parathyroid hor-
mone (iPTH) [4,5] or serum immunoreactive Epo [6-8]
and the severity of the anaemia in uraemic patients.
Indirect evidence suggests that high serum iPTH values
could be implicated in the impaired production of Epo
encountered in these patients [9]. Recent findings
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demonstrate that serum iEpo values increase after
parathyroidectomy (PTx) in dialysis patients with
secondary hyperparathyroidism [9,10]. It has also been
shown that anaemia could improve after PTx ir. many of
these patients [11-13]. In addition, hyperparathyroid-
ism has been associated with a relative resistance to the
effects of recombinant human erythropoietin (rHuEpo)
treatment in dialysis patients [1].
If haematocrit does not correlate with serum Epo,
other erythropoietic factors should be considered. A
major candidate for this is growth hormone (GH) and
its cellular mediator, insulin-like growth factor I
(IGF-I). There is growing evidence indicating that GH
stimulates erythropoiesis in vitro and in vivo indepen-
dently from Epo [14,15]. Moreover, erythroid colony-
forming units (CFU-E) require direct interaction with
IGF-I and/or insulin for development [16]. It has also
been suggested that insulin and IGF-II stimulate DNA
synthesis and proliferation of CFU-E additively through
a similar receptor or postreceptor system [17]. IGF-I has
a supportive effect on the proliferation and differen-
tiation of erythroid precursors and its action is synergis-
tic to that of Epo [18]. Furthermore, a recent animal
study has shown that during accelerated growth, IGF-I
but not Epo correlates with the increase in red cell mass
[19].
The purpose of the present study was to investigate
whether serum IGF-I values were correlated with the
degree of anaemia in dialysis patients with severe
secondary hyperparathyroidism.
Methods
Patients
Seventeen consecutive patients with chronic renal fai-
lure and severe secondary hyperparathyroidism (11 men
and 6 women) who were admitted to the Nephrology
Department of the Necker Hospital, Paris participated
in the study. Their mean (± SEM) age was 46.1 ± 3.5
years and their mean (± SEM) duration of dialysis was
8.9 ± 1 . 0 years. Underlying nephropathies were as
follows: nephrosclerosis 2, chronic interstitial nephritis
3, polycystic kidney disease 3, chronic glomerulonephri-
tis 3, hereditary nephropathy 2, and unknown 4. No
patient was receiving rHuEpo, steroids, or androgens.
None had malnutrition or hepatic dysfunction. How-
ever, the nutritional status and in particular the dietary
habits of the patients have not been precisely evaluated.
All patients underwent maintenance haemodialysis
thrice weekly and were dialysed with their usual dialysis
membranes, either of synthetic or cellulosic type. Ace-
tate or bicarbonate dialysates were used and dialysate
calcium concentration was 1.75 mmol/litre.
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Serum Biochemistries
Blood samples were obtained after a 12-h fast before a
dialysis session. Plasma calcium was measured using
atomic absorption spectrometry and plasma phosphorus
using a Technicon Auto Analyzer. Plasma alkaline
phosphatase activity was measured by an automated
method (normal range: 30-90 IU/iitre). Serum intact
PTH (iPTH) was measured using a commercial radioim-
munometric assay for intact human PTH (Allegro Intact
PTH, Nichols Institute, San Juan Capistrano, Calif,
USA). The normal range was 10-65 pg/ml. Plasma
aluminium (Al) was determined using atomic
absorption spectrometry with a graphite oven.
Serum insulin-like growth factor I (IGF-I) was deter-
mined after an acid-ethanol extraction as described by
Daughaday et al [20], using a radioimmunoassay
method (RIA) employing a rabbit antihuman IGF-I
antiserum (insulin-like growth factor I/somatomedin C
reagent pack for RIA, Amersham, International pic,
Amersham, UK; normal range, 53-120 ng/ml; mean ±
SEM, 91.9 ± 6.4 ng/ml; n = 13). Serum iEpo concentra-
tions were determined by radioimmunoassay as des-
cribed elsewhere [21]. Normal values in healthy adults
with this assay are between 11 and 31 mU/ml (95%
confidence interval; mean, 17.9 ± 6 mU/ml, n - 84).
Statistical Analysis
Results have been expressed as means ± SEM. The
significance of the magnitude of correlation coefficients
between biochemical values was assessed by linear
regression analysis.
Results
Mean ± SEM concentrations of haemoglobin, haematoc-
rit, and reticulocytes were 9.3 ± 0.5 g/dl (n = 16), 28.6
± 1.8% (n = 15), and 52900 ± 7385 /mm3 (n = 10)
respectively. Marked secondary hyperparathyroidism
was present in all patients, with serum iPTH levels and
plasma alkaline phosphatase activities of 988 ± 88 pg/ml
(n = 17) and 461 ± 85 IU/litre (n = 17) respectively.
Mean serum iEpo and IGF-I values were 20.3 ± 4.7
mU/ml (n = 13) and 320 ± 26 ng/ml (n = 17) respecti-
vely. Total plasma calcium, phosphate, and aluminium
concentrations were 2.62 ± 0.06 mmol/litre (n = 17),
2.12 ± 0.13 mmol/litre (n = 17), and 1.9 ± 0.2 nmol/litre
(n = 16) respectively. Serum iron and ferritin concen-
trations were 16.8 ± 4.0 umol/litre (n = 15) and 274 ±
114 ng/ml (n = 15) respectively.
We found a significant linear correlation between
serum IGF-I and haematocrit values as shown in Fig. 1.
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Fig. 1. Relationship between serum immunoreactive insulin-like
growth factor I (IGF-I) and haematocrit.
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Fig. 2. Absence of a significant relationship between senim immuno-
reactive erythropoietin (lEpo) and haematocrit.
By contrast, serum iEpo values were not correlated with
haematocrit values (Fig. 2). No correlations were found
between serum iPTH, iEpo and IGF-I or between
serum iPTH and haematocrit. In addition, no cor-
relation existed between IGF-I and the other biochemi-
cal parameters measured.
Discussion
In the present study we found that in an anaemic dialysis
patient population with overt secondary hyperparathyr-
oidism, not receiving rHuEpo treatment, serum IGF-I
concentrations were positively correlated with haema-
tocrit values. In contrast, no correlation was found
between serum iEpo and haematocrit values.
In uraemic patients, serum iEpo values are known to
be inappropriately normal or reduced in relation to the
degree of anaemia and to correlate rather poorly with
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haematocrit [6-9]. Numerous other factors have been
suggested to play a role in the anaemia of such patients
including PTH excess. Several hypotheses have been
proposed to explain the part played by secondary
hyperparathyroidism, including a direct inhibitory
effect of elevated serum iPTH on erythropoiesis and/or
Epo activity [2], osteitis fibrosa with medullary fibrosis
[3,11,12], hyperphosphataemia with secondary
increases in red blood cell glycolytic rate, adenosine
triphosphate production and 2,3-DPG formation, caus-
ing a right shift of the haemoglobin/oxygen dissociation
curve and better tissue oxygenation leading to reduced
Epo production [22], and finally, a possible hypercal-
caemia-related decrease in Epo release [23]. However,
as stated previously, no correlation could be demon-
strated between serum iPTH or iEpo values [4-8] and
the degree of anaemia in uraemic patients with severe
hyperparathyroidism. Moreover, only the degree of
marrow fibrosis appeared to predict at least partially the
correction of anaemia in response to PTx [3,12]. Never-
theless, it has been suggested recently that Epo pro-
duction might improve after PTx since serum iEpo may
considerably increase in at least some of the patients
[9,10]. This could also explain the amelioration of the
anaemia after correction of the hyperparathyroid state
[9]-
Factors other than Epo probably play a role in
regulating erythropoiesis, including insulin-like growth
factors (IGFs). IGFs are known serum peptides which
are structurally related to insulin, and IGF-I is secreted
by the liver in response to GH secretion. They have
mitogenic as well as insulin-like activities and are
thought to mediate GH action at the tissue level [24,25].
IGF-I is a small molecule of 7649 Da and is bound to
high-molecular-weight protein carriers of 40000 to
15000 Da. A certain degree of variability has been
reported for serum IGF-I concentrations in uraemic
patients [26-28], possibly due to methodological
problems of IGF-I measurement and to the presence of
plasma IGF-I binding proteins [28-30]. The results of
our study, using a radioimmunoassay after acid-ethanol
extraction, are in accordance with those of Andress et al
[31] who found increased levels of serum IGF-I in
uraemic hyperparathyroid patients.
Recently, serum IGF-I has been suggested as a
marker of bone formation as well as of nutritional status
in haemodialysis patients [31,32]. In addition, a slight
improvement of anaemia and increased serum IGF-I
concentrations were found after the administration of
recombinant human GH to uraemic children on renal
replacement therapy [33], and the occurrence of anae-
mia has been observed after the administration of a GH
and IGF-I antagonist, namely somatostatin [34]. Theor-
etically, it is probable that IGF-I is implicated in the
regulation of erythropoiesis in man. Two pieces of
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evidence support this hypothesis. First, IGF-I is
required for CFU-E development [14-16,35,36] and has
a supportive effect on the proliferation and differen-
tiation of erythroid precursors, in synergy with Epo
[18]. Second, serum IGF-I but not serum iEpo levels,
correlate with erythropoiesis during accelerated growth
in rats [19].
However, to the best of our knowledge, a relationship
between serum IGF-I and anaemia has not been des-
cribed in uraemic patients. It has been reported that a
peptide of approximately 8000 Da which was isolated
from an anephric subject, was capable of regulating late
erythropoiesis [37]. The N-terminal sequence of this
peptide has recently been shown to be identical to that
of IGF-I by Congote et al [38] who suggested that IGF-I
could replace erythropoietin as a stimulator of erythro-
poiesis in some patients with anaemia and renal failure.
Similarly, Buemi et al proposed that this peptide could
be responsible for the faster and more marked response
to rHuEpo observed in anephric patients [39]. It is
therefore tempting to speculate that IGF-I could play an
important part in the erythropoiesis of uraemic patients
with anaemia.
The positive correlation between IGF-I and haema-
tocrit values had a coefficient of only 0.68. This could be
partly due to the action of other erythroid colony-
stimulating hormones such as Epo but also to a dec-
reased IGF-I activity in uraemic serum secondary to the
accumulation of a low-molecular-weight inhibitor nor-
mally cleared by the kidney [29,31]. The latter could
lead to a decreased tissue sensitivity to IGF-I. A similar
mechanism of end-organ resistance to GH has been
proposed to explain growth retardation in uraemia
despite elevated serum GH levels [40].
In summary, we have found that immunoreactive
serum IGF-I but not iEpo values directly correlated
with haematocrit in haemodialysis patients with severe
secondary hyperparathyroidism. IGF-I could be an
important factor regulating erythropoiesis in uraemic
patients. Further studies are needed to characterise this
correlation and possible interactions with the nutritional
status and other variables in order to define the precise
role of IGF-I in the anaemia of uraemic patients with
and without secondary hyperparathyroidism.
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